Syngene International Limited announces IPO - Album
Fotocorp

Syngene International Limited announces IPO

Date: 16-07-2015 | Total Images: 18

Peter Bains, Director& CEO, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:21:00
Peter Bains, Director& CEO, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:21:00
Peter Bains, Director& CEO, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:20:00
Peter Bains, Director& CEO, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:20:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:19:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:18:00
Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:16:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:16:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:16:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:09:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:03:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:03:00
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Kiran Muzumdar Shaw, MD, Syngene International LTD gestures during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:03:00
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:02:00
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD addresses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:02:00
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD poses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD & Kiran Muzumdar Shaw, MD, Syngene International LTD poses during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 18:01:00
Peter Bains, Director& CEO, Syngene International LTD interacts with Kiran Muzumdar Shaw, MD, Syngene International LTD during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Peter Bains, Director& CEO, Syngene International LTD interacts with Kiran Muzumdar Shaw, MD, Syngene International LTD during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 17:58:00
M B Chinappa, CFO, Syngene International LTD, Peter Bains, Director& CEO, Syngene International LTD, Kiran Muzumdar Shaw, MD, Syngene International LTD & Manoj Nerurkar, COO, Syngene International LTD during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
M B Chinappa, CFO, Syngene International LTD, Peter Bains, Director& CEO, Syngene International LTD, Kiran Muzumdar Shaw, MD, Syngene International LTD & Manoj Nerurkar, COO, Syngene International LTD during the press conference to announce Initial Public offer in Mumbai on Thursday, 16 July 2015. Pharmaceutical company Biocon Ltd has fixed a price band for an initial public offering (IPO) of its subsidiary Syngene International Ltd at Rs.240-250 per equity share.
Photographer: Ganesh Lad
Uploaded: 16-07-2015 17:56:00